Karyopharm Therapeutics Future Growth
Future criteria checks 2/6
Karyopharm Therapeutics is forecast to grow earnings and revenue by 14.1% and 21% per annum respectively while EPS is expected to grow by 42.8% per annum.
Key information
14.1%
Earnings growth rate
42.8%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 21.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Dec 24Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
Oct 01Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet
Apr 27Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%
Feb 23Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Feb 05Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified
Apr 17Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 17Karyopharm: Market Is Overlooking Growth
Oct 07Karyopharm Therapeutics Q2 2022 Earnings Preview
Aug 03Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
Jul 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 207 | -84 | N/A | -73 | 5 |
12/31/2025 | 166 | -125 | N/A | -123 | 6 |
12/31/2024 | 153 | -79 | N/A | -134 | 6 |
9/30/2024 | 148 | -87 | -120 | -120 | N/A |
6/30/2024 | 146 | -90 | -131 | -130 | N/A |
3/31/2024 | 140 | -141 | -118 | -118 | N/A |
12/31/2023 | 146 | -143 | -93 | -93 | N/A |
9/30/2023 | 146 | -140 | -101 | -101 | N/A |
6/30/2023 | 146 | -142 | -100 | -100 | N/A |
3/31/2023 | 148 | -158 | -109 | -109 | N/A |
12/31/2022 | 157 | -165 | -150 | -150 | N/A |
9/30/2022 | 250 | -88 | -97 | -97 | N/A |
6/30/2022 | 251 | -104 | -99 | -93 | N/A |
3/31/2022 | 234 | -108 | -119 | -113 | N/A |
12/31/2021 | 210 | -124 | -113 | -107 | N/A |
9/30/2021 | 119 | -206 | -169 | -163 | N/A |
6/30/2021 | 102 | -208 | -184 | -184 | N/A |
3/31/2021 | 113 | -201 | -168 | -168 | N/A |
12/31/2020 | 108 | -196 | -160 | -160 | N/A |
9/30/2020 | 91 | -201 | -169 | -169 | N/A |
6/30/2020 | 83 | -189 | -161 | -161 | N/A |
3/31/2020 | 59 | -186 | -169 | -169 | N/A |
12/31/2019 | 41 | -200 | -191 | -191 | N/A |
9/30/2019 | 23 | -209 | -201 | -200 | N/A |
6/30/2019 | 10 | -216 | -203 | -202 | N/A |
3/31/2019 | 20 | -206 | -193 | -191 | N/A |
12/31/2018 | 30 | -178 | -161 | -159 | N/A |
9/30/2018 | 32 | -159 | -118 | -116 | N/A |
6/30/2018 | 31 | -142 | N/A | -100 | N/A |
3/31/2018 | 12 | -138 | N/A | -84 | N/A |
12/31/2017 | 2 | -129 | N/A | -74 | N/A |
9/30/2017 | 0 | -117 | N/A | -88 | N/A |
6/30/2017 | 0 | -112 | N/A | -87 | N/A |
3/31/2017 | 0 | -112 | N/A | -86 | N/A |
12/31/2016 | 0 | -110 | N/A | -84 | N/A |
9/30/2016 | 0 | -112 | N/A | -85 | N/A |
6/30/2016 | 0 | -117 | N/A | -90 | N/A |
3/31/2016 | 0 | -119 | N/A | -97 | N/A |
12/31/2015 | 0 | -118 | N/A | -94 | N/A |
9/30/2015 | 0 | -115 | N/A | -86 | N/A |
6/30/2015 | 0 | -104 | N/A | -77 | N/A |
3/31/2015 | 0 | -88 | N/A | -61 | N/A |
12/31/2014 | 0 | -76 | N/A | -51 | N/A |
9/30/2014 | 0 | -62 | N/A | -49 | N/A |
6/30/2014 | 0 | -52 | N/A | -41 | N/A |
3/31/2014 | 0 | -42 | N/A | -36 | N/A |
12/31/2013 | 0 | -34 | N/A | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KPTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KPTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KPTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KPTI's revenue (21% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: KPTI's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KPTI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 21:56 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Colleen Kusy | Baird |
Peter Lawson | Barclays |
Ying Huang | BofA Global Research |